Can-Fite BioPharma (NYSE:CANF) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note issued to investors on Sunday. The brokerage issued a sell rating on the stock.

A number of other analysts also recently issued reports on the stock. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, December 31st. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Price Performance

CANF opened at $1.56 on Friday. The stock has a market capitalization of $5.52 million, a price-to-earnings ratio of -0.87 and a beta of 1.36. The business has a 50-day moving average of $1.66 and a two-hundred day moving average of $2.20. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.